

PRESS RELEASE

January 30<sup>st</sup>, 2020

## All patients enrolled for ChloraSolv01

RLS Global is pleased to announce that all patients are included in the study ChloraSolv 01, which has been performed on nine sites in Sweden. The inclusion criteria for the study are chronic wounds below the knee. The aim with the study is to obtain clinical data to regulatory extend the indication for use (diabetic foot ulcers) to all types of chronic wounds below the knee (venous leg ulcers, arterial/mix wounds etc.). ChloraSolv01 is a pilot study. The patients are treated with ChloraSolv for six weeks with six weeks follow up. We are measuring, among other things, the differences of devitalized tissue (necrotic tissue) and the wound and the reduction of wound size.

*"More clinical validation is important in RLS's strategy to establish ChloraSolv as a standard treatment for debridement. It is also an important milestone for RLS that all patients are enrolled for ChloraSolv 01, says Karin Fischer, CEO RLS Global. "RLS takes the opportunity to thank you all patients, investigators and the clinical staff for the contribution in the clinical trial".*

According to industry standard, the data base will be locked, and the study will be un-blinded for data analysis after the last patient has completed the last visit of the study. All data is quality assured. The main result is estimated to be available about eight weeks thereafter. "We expect to be able to communicate when the study result is clear in connection with the completion of the data analysis in Q2 2020". The publication of ChloraSolv01 is expected in autumn 2020.

### Contact information

Karin Fischer, CEO

E-mail: [karin.fischer@rlsglobal.se](mailto:karin.fischer@rlsglobal.se)

Phone: +46 702 48 46 51

Mats Ahlenius, CTO

E-mail: [mats.ahlenius@rlsglobal.se](mailto:mats.ahlenius@rlsglobal.se)

Phone: +46 707 41 03 39

### Trading place and certified advisor

RLS Global's shares has been listed on the Nasdaq First North since 17th May, 2017 and trading takes place under the short name RLS. Certified Adviser is Erik Penser Bank, telephone +46 8 463 83 00, Email: [certifiedadviser@penser.se](mailto:certifiedadviser@penser.se). During the period 2012 - 2017, the company was listed on Aktietorget.

### About RLS Global AB

RLS Global AB is a medical technology company within Life Science. Based on the company's unique hypochlorite platform, RLS Global develop products for some of our most common illnesses in wound and oral care. RLS Global has a portfolio of strong brands, including ChloraSolv®, Perisolv® and Carisolv®. The company is listed on Nasdaq First North with Erik Penser Bank as Certified Adviser, telephone +46 (0) 8 463 83 00, email: [certifiedadviser@penser.se](mailto:certifiedadviser@penser.se). Read more at [www.rls.global](http://www.rls.global)